

EXTRAORDINARY PUBLISHED BY AUTHORITY

ISLAMABAD, TUESDAY, OCTOBER 30, 2012

PART II

Statutory Notifications (S. R. O.)

GOVERNMENT OF PAKISTAN

DRUG REGULATORY AGENCY OF PAKISTAN MINISTRY OF NATIONAL REGULATIONS AND SERVICES

NOTIFICATION

Islamabad, the 23rd October, 2012

- S. R. O. 1349 (1)/2012.—In exercise of the powers conferred by Section 12 of the Drugs Act, 1976 (XXX of 1976), the Federal Government is pleased to fix the Maximum Retail Prices (MRPs) specified in Column 3 of the table below on which the drugs manufactured /imported by various pharmaceutical firms specified in column 2 thereof shall be sold subject to the followings conditions namely:—
 - Valid Drug Manufacturing License / Drug Sale License and Drug Registration(s);
 - The manufacturers and importers of drugs shall furnish MRPs of drugs to the competent authority;
 - Print the retail price on the label in the manner prescribed by the Drugs (Labeling and Packing) Rules, 1986;

(5577)

[3148(2012)/Ex. Gaz.]

Price: Rs. 5.00

- MRPs shall be applicable from the date of the issuance of this notification and stickers are not allowed; and
- Raw material used for drug manufacturing shall be purchased from established source as per official pharmacopoeia under Section 3 of Drugs Act 1976.

7	a	h	1	4
-	-	•		

1 3 S. No. Composition of drug MRP / Pack Size Envepe Tablet Each tablet contains:-Rs. 130.00/30's Doxylamine Succinate......10mg Vitamin B6.....10mg (Maple) Venofer injection 5ml .Rs. 520.00/1's Each Imi contains:-Iron (III)-hydroxide sucrose complex.....20mg (RG Pharmaceuticals) (Import) Maltofer Syrup Each ml contains: Rs. 200.00/120 ml Iron (III) Hydroxide Polymaltose Complex 35.7mg corresponding to Iron (III)10mg (Pharmatec) Folic acid Tablet Each tablet contains: Rs. 30.00/100's Folic acid 5mg (Zafa) 5. Inderal 10 mg Rs. 65.00/50's AkzoNobel Inderal 40 mg AkzoNobe! Rs.153.00/50's

	. 1	2	8 8	海 裕	3
	7.	Optalidon Tablets	30000 47	00237.11	Rs.174.00/200's
		Each tablet contains:-			
	\$50	Propyphenazone175mg		28	
		Caffeine25mg			689
		(Novartis)	2224		
		20	# %		
	8.	Spasmo Cibalgin Tablets	80	58°	Rs.271.00/100's
		Each tablet contains:-	35 2007 - 20		22
	696 - 8	Propyphenazone2			
8		Hexahydroadiphenine HCI2	Omg		
		(Novartis)			
		100 100 100 100 100 100 100 100 100 100	0.80		Rs.57.00/1x1ml
	9.	Sustanon Injection 250mg			KS.57,00/1X11111
	8	Each vial contains:	40	ř	£0
		Testosterone Propionate	30mg	87	
	108	TestosteronePhenylpropionate.	gmuo		
		Testosterone Isocaproate		28	94.0
	**	Testosterone Dacanoate	100mg	•	
		(OBS)			5
	100	Aldomet Tablets 250mg			Rs.429.00/100's
	10.	Each tablet contains:			6
		Methyldopa	250mg		
					8
		(OBS)	20		*
	11	Spasier Neo Tablets	68		Rs. 175.00/30's
	17.	Each tablet contains:			
•		Mebeverine HCI	135mg		88
		(AGP)			91
		(ASC)			
	12.	Cycopin Tablet			Rs 4800,00/40's
	20.70	Mycophenolate Mofetil 500 m	ng		26
		Biocare	N at iv		
		35/			
	13	. Cycopin Tablet		(9)	Rs.2335.00/40's
	1525	Mycophenolate Mofetil 250 n	ng		M W
		Biocare			
				2000	

Rs.119.00/tx14's

Each capsule contains;-

(Saffron)

Esomeprazole 20 mg

PART [[]	THE	GAZETT	E OF PAKIS	TAN, EXT	RA., OCT. 3	0, 2012	*5581
1		2		50.0 50.0 70.0 70.0 70.0 70.0 70.0 70.0		. 3	
21.	Amlodip	ine Tab	lets 5mg	33324	1	Rs.35.0	0/20's
30	Each tub	let contai	ns:		28 88		
	Amlodip	ine	5mg			277	
	(Zafa)		¥	98 188			99 99
22.	Human	Recomb	inant Insul	in Regula	r Injection	Rs.530.	00/vial
	Each for				78		183
	Human i	Recombin	ant Insulin.		100 IU		
ŝ.	(Getz)	- 69	(4)	ii.			
23.	Human	Recomb	inant Insul	in N NPF	I Injection	Rs.530	.00/vial
	Each 10r	ni contair	ns:				
	Human l	Recombin	nant Insulin		100 IU.	(593)	
	(Getz)						
24.			inant Insu	lin 70/30	Injection	Rs.472.00	V10mI vial
		ml contair					
	Human :	Recombi	nant Insulin	** ********	.100 IU		
	(Getz)						26 28
25.	Ibuprol	en + Ps	eudoephed	rine Susp	ension	Rs.30	7/60ml
X8	Each 5m	d contain	8:	****			
5%	Ibuprofe	en	100	Umg			
	Pseudoe	phedrine	HC115	img		86	
	(Saffron) .		000 . 000.000	35 W		
26.	Diclofe	nac Sodi	ium + Mise	aprostol I	Fablets	Rs.230	0.00/20's
2		olet conta				100	
			um	75mg	¥2.	356	
	200-000020000 - 200	0.000	2	-0.090090 ID-2700	800	20	
*	(Saffror		96.00.00				
27.	L-Orni	thin L-A	spartate +	Nicotina	mide +	Rs.140.	00/120ml
500 E.V.	10000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	vin Syru			15 15		
		ml conta	3 7 40				
			partate	.300mg			
399				·			

Nicotinamide......24mg Riboflavin.....0.76mg

(Saffron)

1	2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	3
28,	Each tablet contains:	Rs.82,00/6's
	Amoxicillin	88 .85
	(CSH)	St.
29,	Amoxicillin + Clavulanic Acid tablet	Ne an accuracy Mod
83	nach tablet contains:	Rs.120.00/6's
	Amoxicillin Trihydrate eq. to Amoxicillin500mg	500 M
	Clavulanic Acid (as pot, Clavulanate125mg (CSH)	
20		82
30.	Amoxicillin+ Clavulanic Acid 1g Tablets Each tablet contains:	Rs.155,00/6's
	Amoxicillin	600 600
	(CSH)	
	3 8	
31.	Amoxicillin+ Clavulanic Acid 156.25mg Suspension	Rs.70.00/60ml
200	Each Sml contains:-	
	Amoxycillin Trihydrate eq. to	
	Amoxycilin base 125mg Clavulanic Acid	*
	(as potassium salt)31.25mg (CSH)	*
32.	Amoxicillin+ Clavulanic Acid 312.50mg	D. Janico
3	anahenziou	Rs.109/60ml
	Each 5ml contains:- Amoxycillin Trihydrate eq. to	3
9	Amoxycilin base	85 B
	-lavulanic Acid	
(as potassium salt)62.50mg	
3, A	Amoxycillin Capsules 250mg	TOTAL MARKAGEMENT AND THE
, t	Each capsule contains: amoxycillin Trihydrate	Rs,310.00/100's
e	q. to Amoxicillin base	
((CSH)	

88	ж	7	ъ.

1

3

34. Ampicillin Capsules 500mg Each capsule contain:

Rs.420.00/100's

Ampicillin Trihydrate
eq. to Ampicillin base......500mg.
(CSH)

35. Ampicillin 125mg/5ml Syrup/susp.

Rs.28.00/60ml

Each 5ml contains:
Ampicillin Trihydrate
eq. to Ampicillin base......125mg.
(CSH)

36. Ampicillin Capsules 250mg

Rs.210.00/100's

Each capsule contain:
Ampicillin Trihydrate
eq. to Ampicillin base......250mg.
(CSH)

 Ciprofloxacin Suspension 125mg/5ml (Novamed) Rs.85.00/60ml

[No. F. 11-6/2012-DDC-(P) (Pt-II).]

ZAHEERUDDIN M. BABAR, Deputy Drug Controller (Pricing).



EXTRAORDINARY PUBLISHED BY AUTHORITY

ISLAMABAD, TUESDAY, AUGUST 6, 2013

PART II

Statutory Notifications (S.R.O.)

GOVERNMENT OF PAKISTAN

DRUG REGULATORY AUTHORITY OF PAKISTAN (National Health Services, Regulations and Coordination Division)

NOTIFICATION

Islamabad, the 5th August, 2013

S.R.O. 707 (I)/2013.—In exercise of the powers conferred by section 10 and sub-section (3) of section 12 of the Drugs Act, 1976 (XXXI of 1976), read with clause (a) of section 7 of the Drug Regulatory Authority of Pakistan Act, 2012 (XXI of 2012) and in supersession of its Notification No. S.R.O. 41(I)/2013, dated the 18th January, 2013, the Drug Regulatory Authority of Pakistan, with the approval of the Federal Government, is pleased to constitute a Drug Pricing Committee comprising of the following, namely:—

(2259)

Price: Rs. 2.00

[1141 (2013)/Ex. Gaz.]

S.No.	Composition	Status
(1)	(2)	(3)
1.	Director Costing and Pricing, Drug Regulatory Authority of Pakistan.	Chairperson
2	Secretaries, Department of Health from each Province or their nominees not below the rank of an officer of BPS-19.	Members
3.	Chief Cost Accounts Officer or Cost Accountant, Ministry of Finance, Government of Pakistan.	Member
4.	Deputy Director General (Pricing)/Deputy Druga Controller (Pricing), Drug Regulatory Authority of Pakistan.	Secretary
5.	Representative of Pakistan Medical Association.	Co-opted Member
6.	Representative of Consumer Rights Commission of Pakistan.	Co-opted Member
7.	Representative of Pharma Bureau (Overseas Investors Chamber of Commerce and Industry).	Observer
8.	Representative of Pakistan Pharmaceutical Manufacturers Association.	Observer

- 2. The terms of reference of the said committee shall be as under, namely:—
 - to fix and review the maximum retail price at which a drug or biological is to be sold subject to approval by the Federal Government;
 - (ii) to advise the Federal Government on matters related to drugs pricing;
 - (iii) to monitor availability of drugs at the approved prices, throughout the country and to give such directions to the Provincial Governments and the Federal Inspectors of Drugs, in this regard, as it may deem fit; and
 - (iv) to issue orders as to the actions to be taken in respect of any contravention of Drugs Act, 1976 (XXXI of 1976) and the Drug Regulatory Authority of Pakistan Act, 2012 (XXI of 2012) regarding pricing matters referred to it by the Federal Inspector;
- 3. The observers on the committee shall not have a right to vote in the decision making.

[No. F. 11-11/2012-DDC (P).]

MUHAMMAD ARSHAD KHAN,

Director Legal Affairs.

PRINTED BY THE MANAGER, PRINTING CORPORATION OF PAKISTAN PRESS, ISLAMABAD, PUBLISHED BY THE DEPUTY CONTROLLER, STATIONERY AND PORMS, UNIVERSITY ROAD, KARACHI.